Trexquant Investment LP Buys 6,809 Shares of Aura Biosciences, Inc. (NASDAQ:AURA)

Trexquant Investment LP boosted its holdings in Aura Biosciences, Inc. (NASDAQ:AURAFree Report) by 64.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,362 shares of the company’s stock after purchasing an additional 6,809 shares during the period. Trexquant Investment LP’s holdings in Aura Biosciences were worth $154,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in AURA. Eventide Asset Management LLC lifted its stake in Aura Biosciences by 3.0% in the third quarter. Eventide Asset Management LLC now owns 3,024,905 shares of the company’s stock worth $27,133,000 after purchasing an additional 89,386 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in Aura Biosciences by 6.1% in the third quarter. Adage Capital Partners GP L.L.C. now owns 2,875,000 shares of the company’s stock worth $25,789,000 after purchasing an additional 165,000 shares during the last quarter. Decheng Capital Management III Cayman LLC lifted its stake in Aura Biosciences by 296.5% in the third quarter. Decheng Capital Management III Cayman LLC now owns 1,163,123 shares of the company’s stock worth $10,433,000 after purchasing an additional 869,790 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in Aura Biosciences by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 14,899 shares of the company’s stock worth $132,000 after purchasing an additional 3,778 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in Aura Biosciences by 52.0% in the fourth quarter. SG Americas Securities LLC now owns 19,140 shares of the company’s stock worth $170,000 after purchasing an additional 6,546 shares during the last quarter. 96.75% of the stock is owned by institutional investors.

Aura Biosciences Stock Up 4.6 %

Aura Biosciences stock opened at $7.52 on Thursday. The company has a market capitalization of $372.56 million, a PE ratio of -4.04 and a beta of 0.37. The firm has a fifty day simple moving average of $7.37 and a two-hundred day simple moving average of $8.02. Aura Biosciences, Inc. has a twelve month low of $5.99 and a twelve month high of $13.50.

Aura Biosciences (NASDAQ:AURAGet Free Report) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.11. As a group, equities analysts expect that Aura Biosciences, Inc. will post -1.8 earnings per share for the current fiscal year.

Aura Biosciences Profile

(Free Report)

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

Recommended Stories

Want to see what other hedge funds are holding AURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aura Biosciences, Inc. (NASDAQ:AURAFree Report).

Institutional Ownership by Quarter for Aura Biosciences (NASDAQ:AURA)

Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.